PTC Therapeutics, gene
PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever gene therapy approved in the United States that is directly administered to the brain.
PTC Inc. PTC is scheduled to report fourth-quarter fiscal 2024 results on Nov. 6. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. For the quarter, PTC anticipates ...
Q3 2024 Earnings Call Transcript November 7, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.39, ...
Berenberg Friday downgraded PTC (NASDAQ:PTC) to 'hold' from 'buy' arguing that the brokerage wasn't seeing any signs of ...
It’s an exciting time because our products are at the epicenter of driving business transformation at our customers,” said Neil Barua, President and CEO, PTC (PTC).
Engineering and design software provider PTC (NASDAQ:PTC) met Wall Street’s revenue expectations in Q3 CY2024, with sales up 14.6% year on year to $626.5 million. On the other hand, next quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback